newsfilter
← Latest News
GlobeNewswire·

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2